Academic Journal
Medication discontinuation in the era of elexacaftor/tezacaftor/ivacaftor: an Australian survey and qualitative interview.
| Title: | Medication discontinuation in the era of elexacaftor/tezacaftor/ivacaftor: an Australian survey and qualitative interview. |
|---|---|
| Authors: | Corbett M; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Saini B; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Dunn A; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Visser S; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Jo H; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Yozghatlian V; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia., Bell J; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Sivam S; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. |
| Source: | Internal medicine journal [Intern Med J] 2026 Jul; Vol. 56 (7), pp. 1240-1244. Date of Electronic Publication: 2026 Jun 19. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 101092952 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1445-5994 (Electronic) Linking ISSN: 14440903 NLM ISO Abbreviation: Intern Med J Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Carlton, Vic. : Blackwell Science Asia, c2001- |
| MeSH Terms: | Indoles*/administration & dosage , Indoles*/therapeutic use , Cystic Fibrosis*/drug therapy , Cystic Fibrosis*/epidemiology , Benzodioxoles*/administration & dosage , Benzodioxoles*/therapeutic use , Quinolones*/administration & dosage , Quinolones*/therapeutic use , Aminophenols*/administration & dosage , Aminophenols*/therapeutic use , Chloride Channel Agonists*/administration & dosage , Chloride Channel Agonists*/therapeutic use , Pyridines*, Australia/epidemiology ; Humans ; Prospective Studies ; Surveys and Questionnaires ; Drug Combinations ; Treatment Interruption ; Pyrrolidines ; Qualitative Research ; Interviews as Topic ; Pyrazoles ; Quinolines |
| Abstract: | Chloride channel potentiator and corrector elexacaftor/tezacaftor/ivacaftor (ETI) has reduced the burden of disease in people with cystic fibrosis (PwCF) and led to some patients ceasing high-burden treatment regimens. This study was a prospective survey and qualitative interview that evaluated medications PwCF had ceased after ETI. It demonstrated that a majority of PwCF have ceased medications, which prompts further research to rationalise medication regimens for PwCF. (© 2026 Royal Australasian College of Physicians.) |
| References: | J Cyst Fibros. 2013 Sep;12(5):461-7. (PMID: 23352205) PLoS One. 2019 Apr 12;14(4):e0213639. (PMID: 30978192) J Cyst Fibros. 2024 Jan;23(1):32-37. (PMID: 37069044) J Cyst Fibros. 2020 Sep;19(5):762-767. (PMID: 31761739) Respir Med. 2025 Nov-Dec;249:108464. (PMID: 41167496) Lancet Respir Med. 2023 Apr;11(4):329-340. (PMID: 36343646) Thorax. 2018 Apr;73(4):388-390. (PMID: 28778919) Pediatr Pulmonol. 2023 Jul;58(7):1931-1941. (PMID: 37097078) |
| Contributed Indexing: | Keywords: Cystic Fibrosis; Elexacaftor/Tezacaftor/Ivacaftor; Treatment burden; Treatment rationalization |
| Substance Nomenclature: | 0 (Indoles) 0 (Benzodioxoles) 0 (Quinolones) 0 (Aminophenols) 0 (Drug Combinations) 0 (Chloride Channel Agonists) 0 (elexacaftor, ivacaftor, tezacaftor drug combination) 0 (Pyrrolidines) 0 (Pyridines) 0 (Pyrazoles) 0 (Quinolines) |
| Entry Date(s): | Date Created: 20260619 Date Completed: 20260729 Latest Revision: 20260813 |
| Update Code: | 20260813 |
| PubMed Central ID: | PMC13409202 |
| DOI: | 10.1111/imj.70464 |
| PMID: | 42318767 |
| Database: | MEDLINE |
| ISSN: | 1445-5994 |
|---|---|
| DOI: | 10.1111/imj.70464 |